Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in non-cirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: the STORM-C-1 phase II/III trial
Late Breakers


Authors

Isabelle Andrieux-Meyer , Switzerland
More ...
Soek-Siam Tan , Malaysia
More ...
Nicolas Salvadori , Switzerland
More ...
François Simon , Switzerland
More ...
Tim R. Cressey
More ...
Hajjah Rosaida Hj Mohd Said
More ...
Muhammad Radzi Abu Hassan
More ...
Haniza Omar
More ...
Hoi Poh Tee , Malaysia
More ...
Wah-Kheong Chan , Malaysia
More ...
Khean Lee Goh , Malaysia
More ...
Sharifah Faridah Syed Omar
More ...
Adeeba Kamarulzaman , Malaysia
More ...
Suresh Kumar , Malaysia
More ...
Satawat Thongsawat , Thailand
More ...
Kanawee Thetket
More ...
Anchalee Avihingsanon , Thailand
More ...
Suparat Khemnark
More ...
Sombat Thanprasertsuk
More ...
Jean-Michel Piedagnel
More ...
Jennifer Brenner , Switzerland
More ...
Sasikala Siva
More ...
Nur Asimah
More ...
Nelson Da Silva
More ...
Bernard Pecoul , Switzerland
More ...
Marc Lallemant , Switzerland
More ...
Shahnaz Murad
More ...